Bahram Valamehr Biography and Net Worth

Insider of Fate Therapeutics

Bahram (Bob) Valamehr is the Chief Research and Development Officer at Fate Therapeutics, overseeing the company’s research and development activities. Previously, Dr. Valamehr has held the positions of Chief Development Officer and Vice President of Cancer Immunotherapy at Fate and prior to that played key scientific roles at Amgen, the Center for Cell Control (a NIH Nanomedicine Development Center) and the Broad Stem Cell Research Center developing novel methods to control pluripotency, to modulate stem cell fate including hematopoiesis and to better understand cellular signaling pathways associated with cancer. He has co-authored numerous studies and patents related to stem cell biology, oncology and materials science. Dr. Valamehr received his Ph.D. from the Department of Molecular and Medical Pharmacology at UCLA, his M.B.A. from Pepperdine University and his B.S. from the Department of Chemistry and Biochemistry at UCLA.

What is Bahram Valamehr's net worth?: The estimated net worth of Bahram Valamehr is at least $319,299.38 as of January 9th, 2024. Dr. Valamehr owns 158,069 shares of Fate Therapeutics stock worth more than $319,299 as of November 17th. This net worth estimate does not reflect any other assets that Dr. Valamehr may own. Additionally, Dr. Valamehr receives an annual salary of $644,500.00 as Insider at Fate Therapeutics. Learn More about Bahram Valamehr's net worth.
How old is Bahram Valamehr?: Dr. Valamehr is currently 47 years old. There are 3 older executives and no younger executives at Fate Therapeutics. The oldest executive at Fate Therapeutics is Mr. J. Scott Wolchko, Founder, CEO, President & Director, who is 54 years old. Learn More on Bahram Valamehr's age.
What is Bahram Valamehr's salary?: As the Insider of Fate Therapeutics, Inc., Dr. Valamehr earns $644,500.00 per year. The highest earning executive at Fate Therapeutics is Mr. J. Scott Wolchko, Founder, CEO, President & Director, who commands a salary of $920,400.00 per year. Learn More on Bahram Valamehr's salary.
How do I contact Bahram Valamehr?: The corporate mailing address for Dr. Valamehr and other Fate Therapeutics executives is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. Fate Therapeutics can also be reached via phone at (858) 875-1800 and via email at [email protected]. Learn More on Bahram Valamehr's contact information.
Has Bahram Valamehr been buying or selling shares of Fate Therapeutics?: Bahram Valamehr has not been actively trading shares of Fate Therapeutics within the last three months. Most recently, Bahram Valamehr sold 11,271 shares of the business's stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $4.38, for a transaction totalling $49,366.98. Following the completion of the sale, the insider now directly owns 158,069 shares of the company's stock, valued at $692,342.22. Learn More on Bahram Valamehr's trading history.
Who are Fate Therapeutics' active insiders?: Fate Therapeutics' insider roster includes Yu-Waye Chu (VP), Edward Dulac, III (CFO), John Mendlein (Director), Louis Petrillo (Insider), Mark Plavsic (Insider), Cindy Tahl (General Counsel), Bahram Valamehr (Insider), and J. Wolchko (CEO). Learn More on Fate Therapeutics' active insiders.
Are insiders buying or selling shares of Fate Therapeutics?: In the last year, Fate Therapeutics insiders bought shares 1 times. They purchased a total of 44,630 shares worth more than $166,023.60. In the last year, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 46,046 shares worth more than $202,409.98. The most recent insider tranaction occured on August, 6th when Director Yuan Xu sold 633 shares worth more than $2,677.59. Insiders at Fate Therapeutics own 5.0% of the company. Learn More about insider trades at Fate Therapeutics.
Information on this page was last updated on 8/6/2024.

Bahram Valamehr Insider Trading History at Fate Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/9/2024	Sell	11,271	$4.38	$49,366.98	158,069
1/10/2023	Sell	10,917	$5.24	$57,205.08	168,917
7/7/2022	Sell	17,158	$30.23	$518,686.34	179,834
1/10/2022	Sell	5,596	$46.38	$259,542.48
12/13/2021	Sell	25,000	$47.66	$1,191,500.00
6/14/2021	Sell	25,000	$89.32	$2,233,000.00	111,896
3/15/2021	Sell	25,000	$92.35	$2,308,750.00	120,740
1/8/2021	Sell	6,230	$117.10	$729,533.00	84,455
1/8/2020	Sell	5,700	$20.69	$117,933.00	91,758
10/15/2019	Sell	6,200	$14.18	$87,916.00

Bahram Valamehr Buying and Selling Activity at Fate Therapeutics

Fate Therapeutics Company Overview

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Today's Range

Now: $2.02

$1.96

$2.12

50 Day Range

MA: $3.11

$2.02

$4.02

2 Week Range

Now: $2.02

$1.96

$8.83

Volume

1,752,594 shs

Average Volume

1,503,266 shs

Market Capitalization

$230.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.88

From Porter & Company | Ad

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.

Bahram Valamehr Biography and Net Worth

What is Bahram Valamehr's net worth?

How old is Bahram Valamehr?

What is Bahram Valamehr's salary?

How do I contact Bahram Valamehr?

Has Bahram Valamehr been buying or selling shares of Fate Therapeutics?

Who are Fate Therapeutics' active insiders?

Are insiders buying or selling shares of Fate Therapeutics?